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Innovative  therapeutic  targets in chronic  sinusitis  with
nasal polypssit
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gAlvos  terapêuticos  inovadores  na  sinu
Our  current  therapeutic  options  for  patients  with  chronic
sinusitis  and  nasal  polyps  consist  of  topical  glucocorticos-
teroids  (GCS),  carefully  indicated  short  episodes  of  oral  GCS,
courses  of  long  term  antibiotics  (speciﬁcally  doxyxycline1)
and  sinus  surgery.  Even  with  this  armamentarium  used  in
combination  with  pre-  and  postoperative  GCS,  studies  show
high  recurrence  rates  of  nasal  polyps,  with  about  80%  of
regrowth  over  12  years.  About  half  of  these  patients  will
require  surgery  again,  some  of  them  more  than  4  surgeries.
There  is  a  clear  unmet  need  for  a  subgroup  of  chronic  sinus-
itis  patients.
In  Europe,  the  US  and  certainly  Australia,  and  possibly
in  other  regions,  most  polyps  are  characterized  by  a  Th2
inﬂammatory  pattern,  with  cytokines  interleukins  (IL)-4,  -
5,  and  -13,  eosinophils  and  IgE  involved.  In  fact,  this  ‘‘type
2  inﬂammation’’  is  associated  with  severe  polyp  disease  all
over  the  world,  and  has  been  demonstrated  to  predict  recur-
rence  of  disease  and  asthma  comorbidity,  different  from
eosinophil-poor  primarily  neutrophilic  polyps.2 This  makes
Th2  cytokines  and  the  associated  inﬂammatory  cells  and
their  products  perfect  targets  for  innovative  therapeutic
interventions.  Very  similar  mechanisms  are  also  involved  in
severe  asthma  and  atopic  dermatitis,  and  thus  we  may  hope
that  treatment  approaches  that  are  developed  for  those  dis-
eases  will  also  one  day  be  available  for  severe  nasal  polyps.
So  far,  there  have  been  several  proof-of-concept  stud-
ies  performed  in  nasal  polyp  disease,  all  in  Ghent,  involving
the  antibodies  reslizumab,  mepolizumab  and  omalizumab.
These  studies  have  shown  that  indeed  the  type  2  inﬂam-
mation  does  play  a  major  role  in  nasal  polyps;  all  three
humanized  monoclonal  anti-bodies  targeting  IL-5  or  IgE  have
been  successful  to  a  certain  extent.3 Although  rather  small,
the  studies  demonstrated  that  polyps  shrink  over  2--3  months Please cite this article as: Bachert C. Innovative therapeutic tar-
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nd  remain  under  control  for  several  months  thereafter,
lthough  treatment  approaches  were  rather  limited  in  time
nd  number  of  injections.  This  stimulated  hope  for  further
chievements  in  the  future,  when  nasal  polyps  would  be
ccepted  as  targets  for  registration  for  major  ‘‘players’’
such  as  GSK,  Sanoﬁ,  Novartis  etc.),  and  larger  studies  would
e  performed  with  the  aim  of  achieving  registration  for  the
ndication  of  nasal  polyps.
This  time  has  now  come.  On  February  2nd,  2016,  a
rst  proof-of-concept  study  with  dupilumab,  a fully  human
iologics  targeting  the  IL-4  receptor  alpha  and  interfering
ith  both  IL-4  and  IL-13  pathways,  has  been  published  in
AMA.4 IL-4  and  IL-13  signal  through  2  different  receptors
hat  partly  overlap  in  their  functions,  and  they  both  con-
ain  the    subunit  of  the  IL-4  receptor.  Via  those  receptors,
L-4  and  IL-13  orchestrate  IgE  formation,  eosinophil  recruit-
ent,  mucus  secretion  and  many  other  ‘‘typical’’  events.
s  both  cytokines  are  prominent  representatives  of  type
 inﬂammatory  reactions,  we  performed  a  double-blind,
lacebo-controlled  randomized  study  on  the  effectiveness
nd  safety  of  dupilumab  in  patients  with  chronic  sinusitis
ith  nasal  polyps  with  or  without  concomitant  asthma.  Polyp
cores  had  to  be  at  least  5  of  8  bilaterally,  and  polyps  had
o  be  refractory  to  topical  GCSs.  Sixty  patients  with  bilat-
ral  nasal  polyposis  were  included  and  observed  for  4  weeks
uring  topical  GCS  treatment  and  then  treated  either  with
00  mg  of  subcutaneous  dupilumab  per  week  (loading  dose
00  mg)  or  placebo  for  16  weeks;  both  groups  were  receiving
aily  mometasone  furoate  nasal  spray.
In  the  verum  treated  group,  the  endoscopic  nasal  polyp
core,  the  CT  score  according  to  Lund  and  Mackay,  and  each
f  the  typical  symptoms  as  well  as  nasal  ﬂow  measurements
mproved  signiﬁcantly  compared  to  the  placebo  treated
roup.  Furthermore,  the  Sino-Nasal  Outcome  Test  (SNOT-
2)  and  the  University  of  Pennsylvania  Smell  Identiﬁcation
est  revealed  clinically  and  statistically  signiﬁcant  effects
ompared  with  placebo.  More  than  half  of  the  patients
esponded  with  a  reduction  of  the  polyp  score  of  at  least
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Ghent  University  Hospital,  Ghent,  Belgium52  
 points,  which  is  the  same  level  of  response  as  3  weeks  of
ral  application  of  GCSs.  The  drug  was  well  tolerated,  with
he  most  frequently  reported  adverse  events  being  naso-
haryngitis,  injection-site  reactions,  and  headache  (not
igniﬁcant).
Asthmatic  patients  additionally  achieved  signiﬁcantly
mproved  pulmonary  function  and  asthma  control  test
esults  in  comparison  with  placebo.  Concen-trations  of
iomarkers  of  eosinophilic  inﬂammation,  including  serum
gE  and  chemokines  for  eosinophils,  were  also  signiﬁcantly
educed  in  serum.  The  results  of  this  study  were  consis-
ent  with  previous  investigations  in  patients  with  severe
sthma  and  atopic  dermatitis  and  conﬁrmed  the  potential
f  dupilumab  to  inhibit  TH2-induced  inﬂammation  and  con-
ecutive  symptoms  and  complaints.
With  this  study,  a  new  dimension  in  the  management  of
asal  polyps  including  comorbid  asthma  may  be  revealed.
f  course,  studies  with  greater  populations  and  different
osing  regimens  have  to  be  performed,  and  registration  of
he  drug  may  still  take  two  years  or  more;  but  for  the  ﬁrst
ime,  a  registration  for  the  indication  of  nasal  polyps  could
e  achieved.  It  will  then  be  our  task  to  deﬁne  the  patient
roups  and  the  timing  of  this  intervention  in  the  ﬂow  of  GCS
reatment  and  surgery.  Biomarkers  might  allow  us  to  select
atients  and  predict  their  response  to  the  treatment,  and
hus  will  have  impact  on  our  management  of  the  disease.
nd  ﬁnally,  other  biologics  will  likely  come  to  follow  this
xample.The  future  has  arrived  for  innovative  treatment  of  severe
asal  polyposis.  This  implies  of  course  not  only  new  perspec-
ives  for  us  and  our  patients,  but  also  the  need  for  making
s  knowledgeable  in  the  immunology  of  the  disease,  theEDITORIAL
ntervention  and  the  possible  adverse  events.  We  need  to
ecome  well  versed  in  this  area,  if  we  want  to  maintain  the
isease  within  our  speciality.
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